Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | CASP1 | P29466 | 1/20 | 0.65 |
| ▸ | CASP7 | P55210 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | GABRP | O00591 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14689628 | 0.88 | MAPT (0.76) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL29172841 | 0.83 | MAPT (0.63) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL29402096 | 0.82 | MAPT (1.00) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL1603150 | 0.82 | MAPT (1.00) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL5022753 | 0.82 | MAPT (0.63) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL14376021 | 0.79 | ABCG2 (0.69) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL1985563 | 0.79 | KMT2A (1.00) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL29391902 | 0.79 | KMT2A (1.00) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL5022693 | 0.77 | KDM4E (0.57) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL5016443 | 0.76 | MEN1 (0.56) | MAPTMEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9962368-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170157092-A1 | Anti-depression Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-06-08 | — | — | US | disclosed |
| US-9616048-B2 | Anti-depression compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160206596-A1 | Anti-depression Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2016-07-21 | — | — | US | disclosed |
| US-9162980-B2 | Anti-depression compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140343018-A1 | Anti-depression Compounds | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2014-11-20 | — | — | US | disclosed |
| US-8877797-B2 | Methods for treating Parkinson's disease using pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-11-04 | — | — | US | disclosed |
| US-8735440-B2 | Methods for treating amyotrophic lateral sclerosis using pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130190273-A1 | Methods for Treating Amyotrophic Lateral Sclerosis Using Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130184271-A1 | Methods for Treating Parkinson's Disease Using Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130040977-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184271-A1 | Methods for Treating Parkinson's Disease Using Pro-Neurogenic Compounds | BDNF, GAP43, NES | MAPT 141/4885MEN1 3574/4885KMT2A 3921/4885 |
| US-20130190273-A1 | Methods for Treating Amyotrophic Lateral Sclerosis Using Pro-Neurogenic Compounds | BDNF, GAP43, DCX | MAPT 122/4885MEN1 3387/4885KMT2A 3924/4885 |
| US-20140343018-A1 | Anti-depression Compounds | BDNF, DCX, GAP43 | MAPT 142/4885MEN1 4295/4885KMT2A 3598/4885 |
| US-20130040977-A1 | Pro-Neurogenic Compounds | BDNF, GAP43, DCX | MAPT 136/4885MEN1 3423/4885KMT2A 3749/4885 |
| US-20160206596-A1 | Anti-depression Compounds | BDNF, DCX, GAP43 | MAPT 142/4885MEN1 4295/4885KMT2A 3598/4885 |
| US-20170157092-A1 | Anti-depression Compounds | BDNF, DCX, GAP43 | MAPT 142/4885MEN1 4295/4885KMT2A 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.